Development of mucoadhesive microspheres for intranasal delivery of fluconazole as an alternative treatment of cryptococcal meningitis infection in patients with acquired immunodeficiency.
Ann Pharm Fr
; 82(5): 813-821, 2024 Sep.
Article
in En
| MEDLINE
| ID: mdl-38604290
ABSTRACT
INTRODUCTION:
Cryptococcal meningitis is a deadly disease with few treatment options. Its incidence is still high and closely linked to the HIV/AIDS epidemic. This study aimed to develop a mucoadhesive microsphere delivery system for fluconazole for the intranasal route.METHOD:
Microspheres of mucoadhesive fluconazole formulation variables such as different amounts of drug concentration and polymer concentration were prepared by a simple emulsion-crosslinking method. The prepared microspheres' surface was characterised by SEM (Scanning electron microscopy) and evaluated for particle size, entrapment efficiency, production yield, infrared spectroscopic study, in-vitro muco-adhesion, and in-vitro drug release.RESULTS:
The results showed that formula 1 is the optimal mucoadhesive microsphere preparation, with a particle size of 56.375m, a spherical surface shape, an entrapment efficiency of 99.96%, and a greater mucoadhesive capability during 6-hour evaluation. Furthermore, wash-off examination revealed that the mucoadhesive ability of this delivery system has a long duration and may release the active material at the right time.CONCLUSION:
The result of the researches suggesting that the formulation of mucoadhesive microspheres of fluconazole could be used to treat cryptococcal meningitis infection in HIV/AIDS patients.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Particle Size
/
Administration, Intranasal
/
Fluconazole
/
Adhesiveness
/
Meningitis, Cryptococcal
/
Microspheres
/
Antifungal Agents
Limits:
Animals
/
Humans
Language:
En
Year:
2024
Type:
Article